Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Janssen"

42 News Found

Janssen Tremfya excels as psoriasis treatment, outshining IL-17s, says GlobalData
News | May 31, 2023

Janssen Tremfya excels as psoriasis treatment, outshining IL-17s, says GlobalData

The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab


Janssen announces novel dengue antiviral demonstrates efficacy in pre-clinical data
News | March 20, 2023

Janssen announces novel dengue antiviral demonstrates efficacy in pre-clinical data

The antiviral is efficacious in non-human primates, and is safe and well-tolerated in humans


Janssen and Eli Lilly collaboration to address lack of pediatric therapies could rescue mirikizumab program, says GlobalData
News | February 06, 2023

Janssen and Eli Lilly collaboration to address lack of pediatric therapies could rescue mirikizumab program, says GlobalData

The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).


Daman collaborates with Janssen to develop digital health tool
Biotech | May 26, 2022

Daman collaborates with Janssen to develop digital health tool

The aim is to provide further insights into patients' lives in the effort to deliver better outcomes for people with psoriatic arthritis (PsA)


Janssen’s icare4u to assist people living with skin, joint and digestive disorders
Healthcare | May 19, 2022

Janssen’s icare4u to assist people living with skin, joint and digestive disorders

The icare4u program features a dedicated website, with comprehensive information about the diseases, videos with medical experts, and a social media community for patients and caregivers on Facebook and YouTube


USFDA approves Janssen’s injectable regimen for HIV
Drug Approval | March 25, 2022

USFDA approves Janssen’s injectable regimen for HIV

Cabenuva was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen's decades-long commitment to combatting HIV


Janssen announces novel mechanism that shows promise against dengue
Biotech | October 07, 2021

Janssen announces novel mechanism that shows promise against dengue

Early-stage research suggests the potential to prevent and treat all dengue serotypes and builds on Johnson & Johnson's work to advance science against emerging and entrenched global public health threats


Janssen announces U.S. FDA approval of Invega Hafyera
Drug Approval | September 02, 2021

Janssen announces U.S. FDA approval of Invega Hafyera

Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months


Cureskin secures US$ 20 million in Series B funding
News | March 14, 2024

Cureskin secures US$ 20 million in Series B funding

Cureskin aims to disrupt the large and growing skin and hair care industry in India


Biocon Biologics secures US market entry date for Bmab 1200
Drug Approval | March 01, 2024

Biocon Biologics secures US market entry date for Bmab 1200

The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA